There is evidence for enhanced hypothalamo ± pituitary ± adrenal axis (HPAA) activity in centrally obese premenopausal women. This has led to the hypothesis that increased cortisol production rates may be an aetiological factor in the genesis of central obesity. However, the relationship of obesity and body fat distribution to HPAA activity in men and postmenopausal women has not been established. We carried out CRH tests in 13 men and 8 post-menopausal women. We measured 24 h urine cortisol metabolites prior to the CRH test in each subject, as an indication of cortisol production rate. There was a signi®cant direct relationship between central obesity as measured by the ratio of subscapular : triceps skinfold thickness (STR) Ð and the ACTHacortisol response to CRH in men, but not in postmenopausal women. There was no relationship between obesity or body fat distribution and 24 h urine cortisol metabolites. This study provides evidence for hyperactivity of the HPAA in centrally obese men, but not in postmenopausal women.
Introduction
The pituitary and adrenal response to corticotrophin releasing hormone (CRH) in obese premenopausal women has been extensively studied. 1 ± 3 However, there is a lack of data on the in¯uence of obesity and body fat distribution on the CRH responses in men and postmenopausal women. We hypothesize that centrally obese men and postmenopausal women also display an enhanced pituitary ± adrenal response to CRH. We control for the in¯uence of depression, previously reported to be associated with a blunted ACTH and a normal cortisol response to CRH. 4 
Subjects and methods
Thirteen men and eight postmenopausal women were studied and their characteristics are outlined in Table 1 . No subjects were being treated with topical, inhaled or oral corticosteroid preparations or had received such treatment in the year prior to the study. Four of the women were taking hormone replacement therapy. Total body fat (TBF) was measured by bioimpedance (Bodystat Ltd, UK). Subscapular ± triceps skinfold thickness ratio (STR) was measured with calipers (Holtain Ltd, UK). All subjects completed a 24 h urine collection for urine total cortisol metabolites immediately prior to the CRH test. A standard CRH test was performed, all subjects receiving 100 mg of human CRH intravenously at 09.00 h. After the CRH test, all subjects completed a GHQ30 questionnaire to assess depression scores. At least 2 weeks after the CRH test, all subjects underwent a 2 mg overnight dexamethasone suppression test.
Results
The 9 a.m. cortisol level was 347 (277 ± 496) nmola1 and did not vary according to gender, body mass index (BMI) or body composition. In men, there were strong correlations between STR and ACTH AUIC (r 0.64, P`0.05), percentage increment (%inc.) in ACTH (r 0.70, P`0.0l) and %inc. cortisol (r 0.55, P 0.05). These relationships remained signi®cant when controlling for depression scores by linear regression analysis. There was a non-signi®cant trend towards enhanced cortisol and ACTH responses with increasing WHR and BMI in men. In the post-menopausal women there was an inverse correlation between STR and ACTH AUIC (r À0.81, P`0.05) and non-signi®cant inverse correlations between STR and cortisol AUIC. There was no relationship between 24 h urine cortisol metabolites and ACTHacortisol responses to CRH in either men or women. All subjects suppressed normally following dexamethasone, excluding Cushing's syndrome.
Discussion
Central obesity in men is associated with an enhanced pituitary ± adrenal response to CRH, independent of depression scores. Cortisol production rates, as indicated by 24 h urine cortisol metabolites prior to CRH testing, did not correlate with CRH responses or adiposity. Thus, we ®nd no evidence for excess production of cortisol in central obesity. Previously, Pasquali demonstrated an enhanced ACTH and cortisol response to CRH in centrally obese premenopausal women. 2 We found no such relationship in postmenopausal women. It is possible that oestrogen de®ciency in the menopause reduces the pituitary and adrenal response to CRH, a hypothesis for which there is supporting in-vitro evidence. 
